Table 2.

Effect of pioglitazone on NTCU-induced lung SCC development

NNormal (%)Hyperplasia (%)Metaplasia* (%)SCC
Control2042.7 ± 3.634.8 ± 3.44.1 ± 0.818.4 ± 1.4
Pioglitazone2052.0 ± 4.133.1 ± 4.94.7 ± 2.112.0 ± 0.6
  • *Combination of metaplasia and dysplasia.

  • Combination of SCC in situ and SCC ± SEM.